Form 4 for HALO HALOZYME THERAPEUTICS, INC.
Accepted 2023-01-18 00:00:00 ET · period of report 2023-01-17 · accession 0001415889-23-001128 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2023-01-18 | 2023-01-17 | HALO | LaBarre Michael J. | SVP, Chief TECHNICAL Off | S - Sale | $50.46 | -10.0K | 143.1K | -7% | -$504.6K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-01-17 | S | D | 8,878 | $50.40 | 144,259 | D | — | — | (F2) Represents a weighted average sales price per share. These shares were sold at prices ranging from $49.89 to $50.85. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
| 2 | Common | Common Stock | 2023-01-17 | S | D | 1,122 | $50.93 | 143,137 | D | — | — | (F3) Represents a weighted average sales price per share. These shares were sold at prices ranging from $50.881 to $50.99. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |